Majority of biotech companies completing an IPO from 1997-2016 achieved product approvals

January 06, 2021

A large scale study from Bentley University of the biotechnology companies that completed Initial Public Offerings from 1997-2016 estimates that 78% of these companies are associated with products that reach phase 3 trials and 52% are associated with new product approvals. The article, titled "Late-stage product development and approvals by biotechnology companies after IPO, 1997-2016," shows that these emerging, public biotechnology companies continue to have a role in initiating new product development, but are no longer distinctively focused on novel, biological products.

The new report from the Center for Integration of Science and Industry at Bentley University, published in Clinical Therapeutics, studied the 319 biotechnology companies focused on new drug development that completed Initial Public Offerings (IPOs) from 1997-2016. These companies contributed to development of 367 products that progressed to phase 3 and 144 new drug approvals through 2016, including 78 New Molecular Entities (NMEs). Key point of the study include:"We see that over two decades, the majority of newly public biotechnology companies are able to successfully initiate development of products that progress to late stage development or approval, most of which are ultimately brought to market by established pharmaceutical firms." " said Dr. Fred Ledley, Director of the Center for Integration of Science and Industry. "Our study also shows that the product portfolio of biotech companies is no longer distinctively focused on novel biological products or methods, but encompasses a wide range of small molecules and reformulations."

This study is one part of a large survey of the finances and late-stage product portfolios of companies with IPOs from 1997-2016, which show that, by the end of 2016, these companies had both created ~$100 billion in shareholder value and spawned 144 new products. While very few of these companies matured into fully integrated pharmaceutical companies, the long term economic performance of these biotech companies, in terms of market capitalization, shareholder value, fraction of companies acquired, and fraction of companies trading or sold above their IPO value, is similar to that of non-biotech companies with concurrent IPOs. Together these studies suggest that the risk of investing in public biotechnology companies is, in part, mitigated by this diversification into technologies with shorter times from IPO to approval and higher probabilities of success.
-end-
This study was authored by Dr. Laura M. McNamee, Dr. Ekaterina G. Cleary, Sunyi Zhang, and Usama Salim along with Dr. Ledley. Ms. Zhang was a graduate researcher, and Mr. Salim an undergraduate researcher, at Bentley University. This work was supported by a grant from the National Biomedical Research Foundation.

THE CENTER FOR INTEGRATION OF SCIENCE AND INDUSTRY at Bentley University focuses on understanding and accelerating the translation of scientific discoveries to create public value. The Center is an environment for thought leadership and interdisciplinary scholarship spanning basic science, data analytics, business and public policy. For more information, visit wwwbentley.edu/sciindustry and follow us on Twitter @sciindustry.

Bentley University is more than just one of the nation's top business schools. It is a lifelong-learning community that creates successful leaders who make business a force for positive change. With a combination of business and the arts and sciences and a flexible, personalized approach to education, Bentley provides students with critical thinking and practical skills that prepare them to lead successful, rewarding careers. Founded in 1917, the university enrolls 4,200 undergraduate and 1,000 graduate and PhD students and is set on 163 acres in Waltham, Massachusetts, 10 miles west of Boston. For more information, visit bentley.edu.

Follow us on Twitter @BentleyU #BentleyUResearch.

For news media only:

Corresponding author: Dr. Fred D. Ledley, Director, Center for Integration of Science and Industry, Bentley University, Waltham, MA. Tel: 781.891.2046; email: fledley@bentley.edu

Bentley University

Related Product Development Articles from Brightsurf:

How anxiety--and hope--can drive new product adoption
When considering new products, anxiety creates approach response (i.e., interest, purchase) rather than avoidance response (i.e., disinterest, failure to purchase) when consumers hope for the goal-congruent outcomes.

Product recommendation systems can help with search of antiviral drugs
Scientists from Skoltech and the Chumakov Federal Scientific Center for Research and Development of Immune-and-Biological Products of RAS checked the ability of artificial intelligence that suggest products to buy, recommend new antiviral compounds.

Chemical recycling makes useful product from waste bioplastic
A faster, more efficient way of recycling plant-based 'bioplastics' has been developed by a team of scientists at the universities of Birmingham and Bath.

Insulins available at US pharmacies are consistent with product labeling
Funding partners JDRF, the American Diabetes Association (ADA), and The Leona M. and Harry B.

Promoting advantages of product category, such as e-cigarettes, can backfire
Researchers suggest that during the past decade, efforts to promote e-cigarettes as a healthier alternative to combustible cigarettes backfired.

Highlighting product greenness may put consumers off buying
New research suggests that companies looking to promote their latest environmentally friendly product should downplay its green credentials if they want consumers to buy it.

Product distribution restraints are not equal research shows
Online shoppers may be pleasantly surprised to find the price of their chosen item has dropped once they've moved to the checkout phase of their purchase.

Towards sustainability -- from a by-product of the biodiesel industry to a valuable chemical
Scientists at Tokyo Institute of Technology (Tokyo Tech) and the National Taiwan University of Science and Technology (Taiwan Tech) develop a cheap and efficient copper-based catalyst that can be used to convert glycerol, one of the main by-products of the biodiesel industry, into a valuable compound called dihydroxyacetone.

Value chain collaboration in new product development yields innovativeness and performance
Businesses looking for a cutting edge in new products find greater innovativeness and better performance of both product and company overall when working with other firms in the same value chain.

Consumers trust influencers less when there is a variety of choices for a product
Consumers have been relying on opinion leader recommendations to make choices about product quality and purchases for a long time.

Read More: Product Development News and Product Development Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.